Rocket製藥 RCKT 深 滬
已收盤 02-06 16:00:00 美东时间
3.16
+0.160
+5.33%
華盛通- 最 高3.22
- 今 開3.10
- 成交量 218.33万股
- 最 低 3.07
- 昨 收 3.00
- 總市值 3.42亿
- 52周最高 11.11
- 市盈率 靜 --
- 換手率 2.02%
- 52周最低 2.19
- 委 比 20.98%
- 總股本 1.08亿
- 歷史最高 67.48
- 量 比 1.15
- 振 幅 5.00%
- 歷史最低 2.19
- 每 手 1
- 風險率 2.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
Kyverna Therapeutics任命Mayo Pujols为首席技术官，接替退休的Karen Walker。Pujols拥有30多年的技术运营经验，曾在Cell和Gene Therapy领域担任高管。他的加入将助力公司推进miv-cel的商业化，并加强CAR T-cell疗法的制造能力。Pujols表示期待与团队合作，加速技术运营以支持公司突破性疗法的上市。
02-03 13:00
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 9, 2025 /PRNewswire/ -- Equity Insider News Commentary – Traditional pharmaceutical strategies are giving ground as breakthrou...
2025-12-10 00:57
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
华尔街顶级分析师最新评级：亚马逊遭下调，Alphabet获上调
如今，华尔街最受关注、对市场走势有影响的研究评级报告已汇总于同一平台。以下是由 The Fly 网站整理的今日投资者需关注的研究评级信息。 五大评级上调案例...
2025-11-19 00:02
JP Morgan Downgrades Rocket Pharmaceuticals to Underweight
JP Morgan analyst Tessa Romero downgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Neutral to Underweight.
2025-11-18 23:28
Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around...
2025-11-18 21:23
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
2025-11-05 03:25
Insider Moves: Rocket, Fair Isaac, Galaxy, Westinghouse, Fastenal
Insiders have been trading these 5 stocks: (($RCKT)), (($FICO)), (($TSE:GLXY)),...
2025-10-18 21:01
美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
2025-10-15 18:20
The FDA Has Accepted The Resubmission Of Rocket Pharmaceuticals' Marketing Application For Kresladi (Marnetegragene Autotemcel; Marne-cel), An Investigational Gene Therapy For Severe Leukocyte Adhesion Deficiency-I. PDUFA Date Is March 28, 2026
Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026All primary and secondary endpoints were met, and KRESLADI was well toleratedRocket is eligible for a Rare Pediatric Disease Priority Review
2025-10-14 19:12
